I don't normally choose dark colors for the background of my blog because I don't like reading "print" that is typed in white. It always hurts my eyes. But I do like to change up the look of my page occasionally and really liked this gray on gray. I played around with the font to make it a little easier on the eyes; it is on mine so I hope it is on yours. But I still didn't like something about it and finally today it hit me. Windy needed to be black and white, not color. I think I like that better. But I have to look at it a few more days to make sure. Maybe I'll just blow the whole gray on gray look and start over!
Back to Wyoming. Wow. I've been home a week; I've worked a week! But my mind is still in Wyoming. Where did I leave off?
Rather than do day long rides, I prefer to ride out in the morning for a longer ride and then let the horses have down time in the afternoon and get a shorter ride in before sundown. This seemed to be working. One morning we left before breakfast and planned to be back from brunch, but it was long after lunch when we returned so the next morning we ate before we rode out. A couple of evenings it rained, but we still got more than enough riding in.
A dehydrated biker stopped at our camp one day to ask for some water. He underestimated his ride and ran out of fluids. As we filled his pack, we quizzed him on where to ride and he mentioned the Twin Mountains had nice trails. He motioned in the general area and Jules and I saw what could be "twin" mountains so made that the next destination.
The next morning, we followed some jeep trails up along the side of the mountain but they would eventually peter out. We couldn't find anything that looked like a bike or horse trail. We'd go up and come back down. Not that it wasn't an interesting ride; any new ride is a nice ride, but we hoped to find a real trail. We finally found it and had a nice ride around the base of what we think was the last twin. It wasn't as long as we hoped, but will remember it and try again another time.
The next day, we trailered over to Vedauwoo Park. We rode here on our last trip and it was worthy of a return. This is when I really missed my traveling buddy, Kathy. She does all the research to find where to go in, where to park and all that jazz and I just follow along. So we were under my directions this time which pretty much had us on our own. We did remember from last time that she said horses were NOT allowed in the public camp or parking areas. We meandered down a dirt road until we found where we believed we parked the last time and saddled up and rode in.
The trails looked the same and they looked different. It's hard to remember from two years ago but whether we were seeing them for the first time or a repeat visit, we were overcome with their awesomeness. (Is that a word?) How did the rock get like this? When was the last time they moved? If a rock moves in the forest does anyone hear it?
We did manage to get ourselves a little bit lost. Lets just say I had a GPS error. If we would have listened to our horses, the ride would have been a few miles shorter.
Coming soon: our last two days. Are you bored yet? Golly, I want to go back.
I am certainly not bored!!!!!! Wowee! Fantastic stuff!
Wow! Those boulders are incredible! Good thing you captured a photo of those rock climbers as they give a better perspective of the true size of those boulders!
Nope, not close to bored - it's great hearing about & seeing your Wyoming trip. You took a lot of great pictures!! Makes me want to go there all the more!
Great pictures. Looks like some awesome scenery and great rides. Glad you found your way home and didn't get ticketed by the rangers. Looks like a lot of fun.
I am not bored at all. I love these long, detailed trip reports. I'm learning a lot.
I also like the grey on grey of the new blog design. Like you, I tend to not enjoy light text on dark background, but this is working for me without any problems.
Can't wait to hear about the last few days.
And Then She Bucked Me Off!


text:
/*
 *
 *  OperationLogDaoImpl 创建于 2016-10-22 12:17:32 版权归作者和作者当前组织所有
 */
package com.mmk.system.dao.impl;

import java.util.HashMap;
import java.util.List;
import java.util.Map;

import org.apache.commons.lang3.StringUtils;
import org.apache.commons.logging.Log;
import org.apache.commons.logging.LogFactory;
import org.springframework.data.domain.Page;
import org.springframework.data.domain.Pageable;
import org.springframework.stereotype.Repository;

import com.mmk.gene.dao.impl.SpringDataQueryDaoImpl;
import com.mmk.system.condition.OperationLogCondition;
import com.mmk.system.dao.OperationLogDao;
import com.mmk.system.model.OperationLog;

/**
* OperationLogDaoImpl: 系统操作日志 数据持久层接口实现
*@author 孙中强
*@version 1.0
*
*/
@Repository
public class OperationLogDaoImpl extends SpringDataQueryDaoImpl<OperationLog> implements OperationLogDao {

    private Log log = LogFactory.getLog(this.getClass());

    public OperationLogDaoImpl(){
        super(OperationLog.class);
    }

    /**
     * 分页查询相关信息,根据传入的bean类对象和分页对象page取得查询结果集List
     * @param operationLogCondition 查询类
     * @param pageable 传入的分页对象
     * @return 符合条件的查询结果集
     * @author 孙中强
     *
     */
    @Override
    public Page<OperationLog> list(OperationLogCondition operationLogCondition,Pageable pageable){
        StringBuffer sb=new StringBuffer("select model from OperationLog model  where 1=1  ");
        Map<String,Object> params = new HashMap<String,Object>();
        if(StringUtils.isNotBlank(operationLogCondition.getUsername())){
            sb.append(" and model.username like :username ");
            params.put("username","%"+operationLogCondition.getUsername()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getRealname())){
            sb.append(" and model.realname like :realname ");
            params.put("realname","%"+operationLogCondition.getRealname()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getFunctionUri())){
            sb.append(" and model.functionUri like :functionUri ");
            params.put("functionUri","%"+operationLogCondition.getFunctionUri()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getFunctionName())){
            sb.append(" and model.functionName like :functionName ");
            params.put("functionName","%"+operationLogCondition.getFunctionName()+"%");
        }
        return queryByJpql(sb.toString(), params, pageable);
    }

    @Override
    public List<OperationLog> list(OperationLogCondition operationLogCondition){
        StringBuffer sb=new StringBuffer("select model from OperationLog model  where 1=1  ");
        Map<String,Object> params = new HashMap<String,Object>();
        if(StringUtils.isNotBlank(operationLogCondition.getUsername())){
            sb.append(" and model.username like :username ");
            params.put("username","%"+operationLogCondition.getUsername()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getRealname())){
            sb.append(" and model.realname like :realname ");
            params.put("realname","%"+operationLogCondition.getRealname()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getFunctionUri())){
            sb.append(" and model.functionUri like :functionUri ");
            params.put("functionUri","%"+operationLogCondition.getFunctionUri()+"%");
        }
        if(StringUtils.isNotBlank(operationLogCondition.getFunctionName())){
            sb.append(" and model.functionName like :functionName ");
            params.put("functionName","%"+operationLogCondition.getFunctionName()+"%");
        }
        return queryByJpql(sb.toString(), params);
    }

    @Override
    public Page< Map<String,Object>> listBySql(OperationLogCondition condition,Pageable pageable){
        StringBuffer sb=new StringBuffer("select id,user_id,username,realname,role_code,role_name,function_uri,function_name,operation_time,status,ip from system_operation_log  where 1=1  ");
        Map<Integer,Object> params = new HashMap<Integer,Object>();
        if(StringUtils.isNotBlank(condition.getUsername())){
            sb.append(" and username like ?3 ");
            params.put(3,"%"+condition.getUsername()+"%");
        }
        if(StringUtils.isNotBlank(condition.getRealname())){
            sb.append(" and realname like ?4 ");
            params.put(4,"%"+condition.getRealname()+"%");
        }
        if(StringUtils.isNotBlank(condition.getFunctionUri())){
            sb.append(" and function_uri like ?7 ");
            params.put(7,"%"+condition.getFunctionUri()+"%");
        }
        if(StringUtils.isNotBlank(condition.getFunctionName())){
            sb.append(" and function_name like ?8 ");
            params.put(8,"%"+condition.getFunctionName()+"%");
        }
        return queryFieldsBySql(sb.toString(), params, pageable);
    }

    @Override
    public OperationLog findBy(String field,Object value){
        StringBuffer sb=new StringBuffer("select model from OperationLog model  where model.");
        sb.append(field);
        sb.append(" = :value ");
        Map<String,Object> params = new HashMap<String,Object>();
        params.put("value",value);
        List<OperationLog> result = queryByJpql(sb.toString(), params,0l,1l);
        return result.isEmpty() ? null : result.get(0);
    }

    @Override
    public List<OperationLog> findAllBy(String field,Object value){
        StringBuffer sb=new StringBuffer("select model from OperationLog model  where model.");
        sb.append(field);
       sb.append(" = :value ");
        Map<String,Object> params = new HashMap<String,Object>();
        params.put("value",value);
        return queryByJpql(sb.toString(), params);
    }

}

redpajama_set_name: RedPajamaGithub


text:
The Oscars: Who I Want to Win This Year
March 2, 2014 February 28, 2014 Shannon A Thompson
Before you indulge in the Oscars like I did, I hope you'll take the time to read my latest interview. When Jera's Jamboree asked me where I get inspiration for my novels, I wasn't sure what I would say, but I am glad she asked. Yes, at 22, I still have night terrors as well as nightmares that are difficult to differentiate from reality, but I also tackled social barriers in this interview. Please read it by clicking here.
Last year, I confessed that my favorite awards show is the Oscars, and I shared who I wanted to win. This year, I am doing the same thing, and I would love to hear who you are rooting for! The ones I completely bolded are the ones I feel the strongest about.
Best Picture: I predict that 12 Years a Slave will win, but I personally loved American Hustle and The Wolf of Wall Street so much that I cannot chose between them.
Actor in Leading Role: Leonardo DiCaprio for The Wolf of Wall Street. Not only does he already deserve an Oscar, he did an amazing job in this movie. His range was unbelievable.
Actress in Leading Role: Amy Adams in American Hustle. Although I truly enjoyed Meryl Streep's performance in August: Osage County, I feel like Adams rocked this role beyond any expectations people had for her.
Actor in Supporting Role: Jonah Hill in The Wolf of Wall Street. I thought he showed serious skill in this roll since he normally does comedies.
Actress in Supporting Role: Jennifer Lawrence for American Hustle. That being said, I found Lupita Nyong'o was really talented in 12 Years a Slave. I thought she played a very difficult role very well. It's just extremely difficult to look at two, very different roles.
Animated Feature Film: Frozen. I don't even feel like it needs an explanation. If you haven't already seen this movie, go watch it now. It's beautiful.
Cinematography: Gravity – which I feel like went (sadly) unnoticed.
Costume Design: The Great Gatsby. I think everyone remembers those costumes. They were beautifully done.
Directing: Gravity – again, I feel like it deserves attention.
Film Editing: Gravity – I saw some of the behind the scenes, and it's absolutely amazing how much which into this movie.
Makeup and Hairstyling – The Lone Ranger – Honestly, I didn't see the other two (Dallas Buyers Club and Jackass Presents: Bad Grandpa) but I still think the makeup was pretty neat in this remake, and I liked that Tonto finally got to say something.
Music: Although it's difficult to remember the soundtracks of these films, I recall Gravity the most.
Music "Original Song" – Let It Go from Frozen. It's safe to say this song went viral for a reason.
Production Design: The Great Gatsby – the scenes were like the clothes, carefully constructed and lively.
Visual Effects: Gravity. The trailer alone blew me away.
Writing: Adapted Screenplay: Philomena: I don't know what will win this category, but Philomena's story is so sad and also very true for many women. I feel like it is a very important movie that many overlooked.
Writing: Original Screenplay: American Hustle or Her: I would just say American Hustle, but I also think Her has some relevance in the world today. I just watched a documentary about Japanese men dating their cell phones instead of their wives.
Topics I'm not voting on (because I don't feel like I've seen enough of the movies.)
Documentary Short Subject
Short Film Animated
Short Film Live Action
Topics I'm not voting on (because I don't know that much about it):
Sound Editing
What do you think? Who are you cheering on tonight?
12 Years a Slave 2014 Oscars Actor in Leading Role Actor in Supporting Role Actress in Leading Role Actress in Supporting Role American Hustle Amy Adams August: Osage County Best Picture Dallas Buyers Club Frozen Gravity interview interview with an author Jackass Presents: Bad Grandpa Jennifer Lawrence Jera's Jamboree Jonah Hill Leonardo DiCaprio Let it go Lupita Nyong'o Meryl Streep Oscar ballot Oscars The Great Gatsby The Lone Ranger The Oscars The Wolf of Wall Street vote for the Oscars Who do you want to win the Oscars Who will win the Oscars
Previous Post February Ketchup
Next Post Why I Am Most Nervous About the Second Book of a Trilogy
26 thoughts on "The Oscars: Who I Want to Win This Year"
Rebecca Meyer says:
Frozen was so great! I hope it wins for Animated Feature. Did you see Dallas Buyers Club? Matthew McConaughey was unbelievable. But I would love to see Leo win an Oscar! 🙂
I didn't see it! I heard that McConaughey is expected to win though, so it must be great. I plan to see it soon. Have you seen his new show, True Detective? It's amazing.
I haven't seen the show, but it looks great! Yes, I just watched Dallas Buyers Club today, and his performance was amazing. It was such a transformation.
Pingback: The Oscars: Who I Want to Win This Year | My Blog
Gabriella says:
If the Academy Awards goes anything like the BAFTAs did then we'll see Gravity win best cinematography, original music and best director! I would love to see Cate Blanchett win best actress for her role in Blue Jasmine.
I need to see Blue Jasmine. I heard her performance was amazing.
I'm tuning into watch my idol Alfonso Cuaron take home the directing Oscar for Gravity. Because of all the success Gravity has achieved, I feel like a proud parent. I've waited for that movie since the day it was announced some 4-5 years ago.
And while I'm here, I'll make a prediction.
Interstellar by Christopher Nolan will be nominated for a shitload of Oscars next year. I read the script for it a month ago and IT IS AMAZING!!!!!!!!
I hope he takes the Oscar for directing, too! Thank you for all the information. I will surely be on the look out for Interstellar.
juliansaba says:
I like Gravity
Reblogged this on jhulle katz raynauld and commented:
jennyinneverland says:
Wow I agree with pretty much everything you just said! I would LOVE Leo to win best actor – as I'm sure most of the female population would after The Wolf of Wall Street haha. He SO deserves that award – his best performance yet!
As for best picture, I also think 12 Years will win but I hope it's either Wolf of Wall Street or Captain Phillips.
I didn't enjoy American Hustle that much but Jennifer Lawrence and Amy Adams definitely deserve awards for their roles because they're both incredible actresses xx
Yeah. I had a lot of the same feelings. You want to show who you want to win, but they often contradict who we think will actually win.
horrorfanatic95 says:
I think for original song u2 will win for ordinary love.
Oh! I need to be more familiar with that song. Going to listen now.
Charles Yallowitz says:
I'll root for any of them who come to shovel the driveway during the snowstorm. 😀 Seriously though, I haven't been paying attention. Saw none of the movies that are up for awards and feel so left out. I agree with you on Dicaprio though.
HAHAH! Oh, I'm in the same boat! We got a snowstorm just last night. We're not moving anytime soon.
They keep shrinking the storm, so I'm hoping by the morning it's one flake that falls in the park that nobody is around to see.
christievmud says:
Great blog! Glad I stumbled upon it. I can't wait for tonight's Oscars, I'll be watching from England so I'll be staying up through the night to watch it. As much as I really want to see Leonardo DiCaprio win his first Oscar I think Matthew McConaughey is going to walk away with it — he was incredible in Dallas Buyers Club! But who knows? I think Jennifer Lawrence is a sure winner, thought. Great post.
I'm glad you enjoy my blog! I agree. I think Matthew McConaughey will win it. I just win Leo would be awarded something by now. I haven't seen Dallas Buyers Club though, but I have seen True Detective. McConaughey is making a stellar comeback.
The Animation Commendation says:
Great list! We agree on some picks. I recently put my list of predictions on my blog. You can check it out if you'd like.
Going to check it out now!
Harliqueen says:
Poor Leo, he missed out yet again! Didn't see the Oscars, but sounds like awards were given to the expected ones to win. I usually just watch it for the dresses! 😀
Did Sandra's spacesuit win best costume?
Lol. No. That went to The Great Gatsby, I believe.

redpajama_set_name: RedPajamaCommonCrawl


text:
Home » Update: Wilson quits Cougars, charging 'abuse'
Update: Wilson quits Cougars, charging 'abuse'
By SPNW Staff November 10, 2012 Updated: November 14, 2012 3 Comments4 Mins Read
In a letter sent to media Saturday afternoon, Marquess Wilson, Washington State's leading receiver, announced he has quit the Cougars football team and charged coach Mike Leach with "abuse," saying his current one-week suspension is a cover-up. The timing was unusual, considering the Cougars were to play UCLA at 7:30 p.m. Saturday.
Here is the text of Wilson's letter:
"Dear Cougar Nation:
"It is with a heavy heart that I announce my decision to forgo playing football for Washington State University. I realize the school is saying that I am suspended for violating team policies and may return next week, but this is a lie. This is an attempt by the athletic department to cover up what is really happening in that locker room.
"It is been a privilege to be a Cougar, to perform on your field and wear the Crimson and Gray. I would like to thank Washington State University for giving me the opportunity to do what I love most, to play football and receive a quality education for the past three years. I'm grateful to the athletic department for the coaching, care and encouragement I have received prior to this season.
"This was going to be our year. My teammates and I were aspiring to be the winning team you deserve. Unfortunately for all, the new coaching staff has destroyed that endeavor. I believe coaches have a chance to mold players, to shape men, to create greatness. However, the new regime of coaches has preferred to belittle, intimidate and humiliate us. This approach has obviously not been successful, and has put a dark shadow on this program.
"My teammates and I have endured this treatment all season long. It is not "tough love". It is abuse. This abuse cannot be allowed to continue. I feel it is my duty to stand up and shed light on this situation by sacrificing my drams, my education and my pride. I resign from this team. I am deeply sorry to those I am letting down. I am not a quitter. I was raised by my family, and many previous coaches to exhibit dedication and embrace sacrifice, but there comes a time when one has to draw a line in the sand.
"Lastly, I thank my fellow teammates, those who also have left the program this year, and those we are leaving behind. I hope our departure will bring awareness to the physical, emotional and verbal abuse being allowed in the locker room and on the field. I pray for healing and recovery for all those who have been hurt by this treatment
Marquess Wilson"
In response to Wilson's statement, WSU athletics director Bill Moos, who hired Leach in Janauary, issued a statement later Saturday night:"
"It is unfortunate that Marquess has chosen not to go through the weekend and have the subsequent visit with me as we had discussed last Tuesday. I was hopeful to provide additional guidance if he was willing to meet the standards that have been set by Mike Leach and his staff in their effort to establish a competitive football program at Washington State. Unfortunately, during times of coaching transitions, departures are not uncommon.
"We have procedures in place that were developed to monitor student-athlete welfare in all of our sports programs. We will continue to follow those procedures and modify them if needed.
"I believe I join many Cougars in wishing Marquess well in his future endeavors. WSU athletics plans no future statement at this time."
Wilson, a junior, was a 2011 All-Pac-12 second-team selection, and a 2011 second-team All-America selection by Yahoo Sports. He set school single-season records last year with 82 receptions and 1,388 yards receiving. He was widely regarded as a 2012 preseason All-American. He is the school's all-time leader in receiving yards.
Wilson had 52 receptions for 813 yards and five touchdowns in 2012.
Paul on November 10, 2012 7:20 pm
So what exactly are these abuses? If not tough love, then please state examples of this abuse. You are sacrificing your education and your football career? Must be heavy stuff. Please elaborate….
Tian Biao on November 10, 2012 11:16 pm
well, i'm not marquess wilson, but just being in Pullman is abuse enough, i would think . . .
jafabian on November 11, 2012 2:04 am
Considering he walked off the team and was suspended for only one game as a result saying that the coaches are trying to cover up abuse simply doesn't make sense at all. No team, college or pro, is going to allow a player to storm out of practice without any repercussion. Wilson says he isn't a quitter but choses to quit the team rather than return from a suspension that he himself initiated.


text:
November Spotlight
by BPI Staff	Thursday, November 16, 2017 4:25 pm
HTTPS://STOCK.AOBE.COM
Crowdsourcing Cancer Research and Biomanufacturing
In June, BioMed X launched two new global calls for application together with Merck KGaA for RNA splicing in cancer and for engineering of high-performance production cell lines. Talented young scientists from top universities and research institutions were invited to submit innovative project proposals and apply for a research fellowship at the BioMed X Innovation Center in Heidelberg, Germany.
BioMed X was founded in 2013 in collaboration with Merck, its first pharmaceutical partner. Since then, its innovation model has attracted sponsorship from four other companies: AbbVie, Boehringer Ingelheim, Johnson & Johnson, and Roche. Currently the organization hosts nine independent research groups from more than 20 different countries. At its innovation center, they work jointly on bioinformatics, consumer care, diagnostics, oncology, neuroscience, and respiratory projects. Four of those research groups began in collaboration with Merck.
The World Health Organization identifies cancer as a leading cause of death worldwide, accounting for 8.8 million deaths in 2015. Emerging data indicate a critical dependency of several subtypes of cancer on a molecular mechanism called RNA splicing. In one new project, Merck seeks to identify novel approaches to exploit tumor-specific RNA-splicing alterations for targeted cancer therapy. A critical factor in cost-efficient manufacturing of modern therapeutics is the productivity of expression cell lines. So in a second project, Merck wants to identify better ways to manufacture monoclonal antibodies (MAbs) and other complex glycosylated proteins.
"We are very pleased to extend our successful collaboration with Merck", said Christian Tidona, founder and managing director of BioMed X. "These two topics will strengthen our expertise in cancer research and add new capabilities in the field of industrial cell engineering." The deadline has passed for applications in these two projects. To be notified of future calls for application or to initiate a collaboration of your own, see the website at www.bio.mx.
HTTPS://STOCK.ADOBE.COM
Collaborations for Cell Line Development, Antibacterial Targets, and Research
Gene design and editing companies Horizon Discovery and ATUM (formerly DNA2.0, Inc.) announced in June a crosslicense agreement for the former's CHO SOURCE platform and the latter's vector technology to speed development of productive, stable cell lines for drug development. Meanwhile, UK medical research charity LifeArc (formerly MRC Technology), Canada's Centre for Drug Research and Development (CDRD), and the UK Defense Science and Technology Laboratory (DSTL), announced a collaboration to identify antibacterial drug targets. And in July, Eli Lilly and Company and Purdue University formed the latter's largest research collaboration with a single company.
Cell-Line Teamwork: Horizon's platform includes a glutamine synthetase (GS) knockout Chinese hamster ovary (CHO) K1 cell line. ATUM will combine that with its own Leap-In transposase technology for cell-line development services. In return, Horizon exclusively licensed an ATUM vector suite for its CHO SOURCE platform, providing a complete cell-line solution to its own customers. These complementary technologies enable expression of complex biologics.
Jeremy Minshull, ATUM's cofounder and CEO, calls this "a very powerful combination for production of stable cell lines in industry-leading timelines." It is suited not just for regular antibodies, but also for the "next wave" of biologics (e.g., two, three, and four-chain bispecifics) and requires only small numbers of clones to be screened for producing commercial titers. "This allows us to look in more depth at other molecule properties, which is essential with more complex biologics."
The CHO SOURCE platform increases stringency of selection over that of historical platforms based around chemical inhibition, providing for rapid identification of clones that express a protein of interest at industry-relevant levels. Developed partly in partnership with Horizon, ATUM's vector suite combines a mammalian expression technology with additional elements that improve aspects of protein production.
Antibiotic-Resistance Partnership: Considering the worldwide health problem of antibiotic resistance, Justin Bryans (executive director of drug discovery at LifeArc) says his company's strategy is to create "communities for impact" (CfI) to work with cutting-edge organizations such as DSTL and the CDRD, "bringing together our diverse expertise and knowledge to tackle key issues in human health. Discovery of new antibacterial drugs is becoming increasingly urgent, and we are excited by the potential of this collaboration. Each party brings a piece of the jigsaw to make a real impact in this field."
Antibiotic resistance is threatening physicians' ability to treat common infectious diseases. A growing list of infections (e.g., pneumonia, tuberculosis, sepsis, and gonorrhea) are becoming harder, even impossible, to treat. In a report published in Review on Antimicrobial Resistance, Dame Sally Davies (the United Kingdom's Chief Medical Officer) says that we have reached a critical point and must act now on a global scale to slow down antimicrobial resistance. The report predicted that bacterial infection risks and resistance to currently available antibiotics will preclude some common medical procedures and operations by 2050. That illustrates the urgency of need for identifying new targets and developing novel antibacterial agents.
To date, most antibacterial drug-discovery programs have focused on very specific aspects of resistance or on single pathogen species. The new collaboration will take a more holistic approach by considering commonalities across pathogens in how genes ("targets") express proteins that give bacteria their drug resistance. Once targets have been selected and scientifically validated, results will be openly published, and the most promising targets will enter into drug discovery programs.
Edie Dullaghan (CDRD's head of target validation) says, "As Canada's national drug development and commercialization center, our goal is to enable development of game-changing therapeutics to address some of the most pressing health issues of our time." His group has assembled a multidisciplinary team of microbiologists, medicinal chemists, and bioinformaticians who will combine their expertise with those of LifeArc and DSTL. "By bringing our distinct perspectives and collective resources to bear, we are uniquely positioned to create an effective path forward for discovery and development of novel antibacterial drugs."
Industry and Academia Working Together: Eli Lilly and Purdue University are moving forward on areas that are core to both institutions. "The biomedical revolution is upon us, but harnessing its full potential will require strong collaboration between academic research centers and industry partners," says David Ricks (Lilly's chairman, president, and chief executive officer). "We look forward to expanding our relationship with Purdue to discover breakthrough solutions for patients."
Their initial research focus areas include developing improved delivery of injectable medicines (to reduce pain, decrease the number of injections, and enable better patient compliance and overall health) and developing predictive models for clinical success (to reduce risks associated with investing in drug development and more effectively predict the outcome of new therapies in humans). The collaborators envision expanding into other areas as well.
Purdue researchers from the natural and physical sciences, engineering, and veterinary medicine will contribute to this interdisciplinary collaboration. Andrew Dahlem (vice president, and chief operating officer at Lilly Research Laboratories) says it "links our two organizations in a commitment to scientific research supporting the global needs of patients." He added that it strengthens "our shared commitment to attract and retain top engineering and technology talent in Indiana."
An EU "New Deal" Project for Inflammatory Bowel Disease Nanotherapy Delivery
A subsidiary of France's nuclear and renewable energy commission, Leti (Laboratoire d'électronique des technologies de l'information) was established in 1967 to pioneer micro- and nanotechnologies in tackling critical challenges in healthcare, energy, and digital migration. This past summer, Leti announced a European Union project to develop a nanotherapy targeting molecules involved in immune-system–associated inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn's disease. An estimated 3 million people in Europe, mostly adolescents and young adults, have been diagnosed with such chronic disorders of the gastrointestinal (GI) tract. Symptoms include diarrhea, fatigue, and abdominal pain, and severe cases can lead to bowel perforation, severe bleeding, colorectal dysplasia, and cancer.
In the four-year, €6 million project, Leti researchers will design nanostructured lipid carriers for in vivo delivery of small interfering RNA (siRNA) molecules across the gut's mucosal barrier. This "New Deal" project is exploring whether a biological therapy using RNA interference (RNAi) and siRNAs can safely treat IBD through specific inhibition of two signal-controlling janus kinases (JAK1 and JAK3). Such approaches have prevented the expression of targeted genes in humans.
Orally administered siRNAs used in the project should allow for specific targeting of inflamed gut in patients with innovative nanostructured lipid carriers embedded in polymer capsules. The latter will protect these nanotherapeutics along the GI tract, whereas the former will enable them to cross mucosal, intestinal wall, plasma membrane, and other barriers of target cells.
Conventional IBD therapies include 5-aminosaliycilates and corticosteroids that are not effective in many patients. Therapeutic antibodies targeting TNFα treat a significant number of IBD patients but are associated with increased infection risk. The new project's treatment would consist of an orally administered siRNA medicine delivered directly to a patient's inflamed gut.
"The New Deal concept could revolutionize IBD therapies for the great benefit of patients and European healthcare systems," said Leti's Fabrice Navarro, project coordinator. "It could strengthen the competitiveness of European biotech and medtech companies in the fields of RNAi medicines and targeted therapy through innovative delivery technologies."
See Angelo DePalma's recent BPI eBook on alternative delivery strategies for information on other such approaches: www.bioprocessintl.com/ebooks.
HTTP://STOCK.ADOBE.COM
Personalized Medicine Coalition Comments on a Landmark FDA Approval
The Federal Drug Administration's (FDA) May 2017 approval of Merck's pembrolizumab (Keytruda) for treating tumors that express one of two biomarkers marks the first time the agency has approved a cancer drug based on biomarkers rather than tumor location. In a June issue of STAT News, Edward Abrahams (president of the Personalized Medicine Coalition) wrote, "Our understanding of cancer has been morphing from a tissue-specific disease — think lung cancer or breast cancer — to a disease characterized more by specific genes or biomarkers than by location."
The new Merck MAb helps a patient's immune system recognize and destroy cancer cells by targeting a specific cellular pathway, making it an immunotherapy. The two targeted biomarkers — microsatellite instability-high (MSI-H) and mismatch repair deficient (dMMR) — affect proper DNA repair inside cells.
Proponents of personalized medicine look toward a future in which physicians use molecular tests to classify different forms of cancer based on the biomarkers they express. Specific treatments will target different biomarkers. Nearly one in four 2014–2016 FDA approvals were for personalized medicines, which now make up the majority of cancer drugs in development, according to Abrahams. However, US regulatory and reimbursement systems have yet to catch up to these advances. Many necessary molecular tests for patients are unavailable because of regulatory uncertainty and consequent low investment in developing them.
Abrahams concluded: "Confronted with unprecedented opportunities in personalized medicine, policymakers would do well to ensure that our research, regulatory, and reimbursement systems facilitate the development of and access to these promising new therapies. Only then can we ensure that Keytruda's groundbreaking approval represents the beginning of a new era that promises better health and a more cost-effective health system." Find the full article online at www.statnews.com/2017/06/21/personalized-medicine-cancer-keytruda-fda.
Growth-Hormone–Deficiency Market Still Growing Steadily
Growth hormone deficiency (GHD) is a global drug market covering the United States, France, Germany, Italy, Spain, Japan, and the United Kingdom. A recent GlobalData report says this market is set to grow from US$1.42 billion in 2016 to ~$2.08 billion by 2026, with a steady compound annual growth rate (CAGR) of 3.9%. Opportunity Analyzer: Growth Hormone Deficiency — Opportunity Analysis and Forecasts to 2026 identifies major drivers of that growth as the launch of long-acting products, improved adherence to and compliance with their use, and increased awareness of GHD among physicians.
GlobalData analyst Edit Kovalcsik explains: "Patient compliance with daily growth-hormone drugs has been a longstanding issue in the GHD treatment landscape and remains the greatest unmet need in the market. This has given a major thrust to innovation in the treatment space, with pharmaceutical companies focusing heavily on developing easier delivery options. Currently, a dominant trend in the GHD market is development of long-acting drugs that can be administered weekly or biweekly." He added that all four late-stage–pipeline drugs and two out of three in early stage development for GHD are long-acting products.
Long-acting growth hormones eventually could replace daily growth hormone treatments. GlobalData predicts them to capture over half of the market by the end of the forecast period. Among them, Pfizer/OPKO's Lagova (hGH-CTP), Versartis' somavaratan, and Novo Nordisk's somapacitan should be the most significant revenue earners by then.
Kovalcsik offers some words of warning: "Following the launch of new long-acting therapies, the level of need for new drugs will be low in the GHD market. Environmental unmet needs — such as earlier diagnosis, disease awareness, and physician education — are of greater priority than designing a new drug in the GHD field."
Hematological and Liver Cancer Pipelines Strong and Invigorated, Respectively
The hematological cancers pipeline — covering leukemia, lymphoma, and myeloma — is the largest oncology therapy area of pharmaceuticals. GBI Research counts 1,474 such programs in active development, 477 of those being first-in-class therapies. As identified in GBI's recent Frontier Pharma publication, First-in-Class Innovation in Hematological Cancers: Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline, cytokine signaling targets make up the greatest proportion of those pipeline and first-in-class programs, followed in both instances by kinases. Those target categories are linked intrinsically as immunotherapies and dominate because of how hematological cancers act on immune cells.
GBI associate analyst Callum Dew explains: "These disorders affect immune cells within the blood and bone marrow, so there is a high degree of pathophysiological crossover between the different types of malignancy within hematological cancers. It is not uncommon for products being developed for this therapy area to be tested across multiple indications." Dew says 214 first-in-class programs are in development for a single indication, but 229 are for two or more, "highlighting the versatility of current pipeline programs." Regarding individual molecular targets, 27.3% of those in the pipeline are first in their classes (more than the industry average). Much promise within this area revolves around targeted immunotherapies.
GBI also examined the liver cancer market recently. Although it currently lacks sufficient approved treatments — two targeted therapies provide limited overall survival benefits — the pipeline is large, diverse, and highly innovative. Another Frontier Pharma report, Liver Cancer: Identifying and Commercializing First-in-Class Innovation, lists 423 products in active development, showing diversity of both molecule type and mechanism of action (MoA). Of 318 products with a disclosed molecular target, 39% are potential first-in-class therapies.
Despite targeted therapies entering this otherwise chemotherapy-dominated market, the prognosis for most liver cancer patients remains extremely poor. Those ineligible for surgery survive for under a year even with treatment. Eligible patients face high recurrence even after surgical tumor resection. So the unmet need here is very high, presenting a strong opportunity for companies developing breakthrough therapies.
GBI managing analyst Dominic Trewartha says, "First-in-class development can be highly lucrative if clinically successful, but is also associated with high risk." First-in-class liver cancer products can be associated with known disease-causing pathways and mutations, but there is no guarantee that such products will live up to their clinical promise and market potential.
The report describes the liver-cancer business landscape as "moderately active, with relatively high-value deals." The mean value for disclosed codevelopment deals is $204 million, and the mean for licensing agreements is $203 million. Companies involved range from start-up biotechs to global leaders.
"Numerous large companies such as Bristol-Myers Squibb and Novartis have a strong track record of in-licensing products," Trewartha continues, "and companies of varying size have acted as licensors, licensees, and codevelopment partners in this indication. Reflecting the pipeline landscape for liver cancer, the MoAs across both licensing and codevelopment deals were diverse. Small molecules constituted the largest group of products in codevelopment and licensing deals, followed by MAbs — mirroring the pipeline."
CPhl Applauds Korea — and Five Years of Annual Reports
The Convention of Pharmaceutical Ingredients (CPhI) returned to the Seoul COEX Convention and Exhibition Center in Korea in August 2017 for its fourth meeting focused on South Korea. Colocated with ICSE, P-MEC, BioPh, and Health Ingredients Korea, this reflects global interest in the Korean pharmaceutical market. The 2017 show reported a 13% increase in the number of exhibitors and more than doubling of overseas buyers since 2015.
A surge in international companies interested in partnerships in Korea highlights a flourishing South Korean drug market. It has become the third largest such region in Asia, with a forecasted growth from $18.6 billion in 2016 to $20.4 billion in 2020. The country's domestic biopharmaceutical market has surged notably over the past five years with a CAGR of 9%.
One major factor for that growth stems from government incentives such as the "Incheon Free Economic Zone," with its goal of becoming one of the world's top economic zones. Another factor is 2006's successful "Bio-Vision 2016" initiative to develop South Korea's biotechnology over 10 years and solidify the country as a global biotechnology leader. A free-trade agreement with the United States has facilitated investments from multinational companies, leading to an internationalization of the regional pharmaceutical market and a drug exports boom. Finally, South Korea's drug industry is known for innovation, having recently topped the Bloomberg Innovation Index.
Chris Kilbee (pharma group director at United Business Media) says, "It is unsurprising that the past few years have seen such a significant surge in international interest. This is an incredibly exciting time for the South Korean pharma market as the region continues to be a global pioneer in innovation, boasting an extremely robust and growing R&D sector."
Five Years of Reporting and Predictions: For the past five years, UBM's CPhI Worldwide has brought together expert panels to produce an annual industry report of analysis and forecasting. For the 2017 edition, the group also looked back at previous annual reports to evaluate the accuracy of their forecasts. Predictions included expanded use of process analytical technology (PAT), quality by design (QbD), serialization, green chemistry, and R&D improvements, as well as the rise of strategic relationships between drug sponsors and contract and development organizations (CDMOs).
A predicted increase in FDA warning letters had been seen as a potential hindrance to the industry. The 2013 annual report suggested this as a result of tightening regulations and a lagging industry in complying with them. This forewarning proved entirely accurate, with FDA warning letters tripling over the past few years — from 4,882 in 2012 to 14,590 in 2016.
The first report predicted a boom in R&D and improvements in drug development cycles. This proved true in 2014 and 2015, with 41 and 45 FDA approvals, respectively. But that increased productivity dropped off significantly in the following years, with just 22 approvals in 2016 and a similar number anticipated for 2017.
PAT, QbD, and serialization have become industry-wide practices improving product quality and efficiency. Another identified trend was the implementation of continuous processing for active pharmaceutical ingredients (APIs) and finished products, and the use of such technologies continues to increase. Annual reports have anticipated that both drug developers and outsourcing providers would begin looking at green chemistry, route scouting, and process improvements early in development with a goal of making less wasteful products. That has begun taking shape across the industry.
CDMOs were predicted to grow in prominence across the industry, with strategic pharma partnerships proliferating. In the past two years, megamergers in this space were expected to become more frequent amid the aggressive competition to become leading and full service providers. The trend is best highlighted by recent deals struck between a number of CDMOs and pharmaceutical companies, as well as the purchase of Patheon by Thermo Fisher. In addition, Big Pharma has set up codevelopment deals with a number of companies to develop and commercialize biologics and biosimilars.
Some of the first annual reports missed the pulse of the industry, however, by expecting tighter regulations to decrease the number of small biotechnology companies entering the market. By contrast, the business environment has heated up significantly in the past couple years, with traditional US hot spots seeing growth while new biotechnology hubs saw rapid emergence — particularly in China.
In the latest CPhI Annual Report, 12 experts provide valuable insight on the current and future state of the industry for manufacturing, R&D, regulations, biologics, PAT/QbD, and innovation, among other topics. 2016's panelists were Gil Roth (president of PBOA, Alan Sheppard (principal at IMS Health), Vivek Sharma (CEO of Piramal Enterprises), Ajaz Hussain (founder and CEO of Insight Advice and Solutions), Minzhang Chen (CEO at STA Pharma, part of WuXi Apptec), Dilip Shah (CEO of Vision Consulting Group), Prabir Basu (pharmaceutical manufacturing and regulations consultant), Brian Carlin (director of FMC), Emil Cuirczak (president of Doramaxx Consulting), Bikash Chatterjee (president and CSO of PharmTech Associates), Girish Malhotra (president of EPCOT International), and Ravi Limaye (president of marketing at Biocon). You can access past reports online at www.cphi.com/europe/cphi-annual-report.
Categories: 2017, November 2017
MT @Bioprocess365: The future is bright for antibody & cellular immunotherapies, with bispecifics and CAR Ts conver… https://t.co/GJl0DpXjLK	2 days ago


text:
You are here: Home / Academic Departments / Sociology / News and Events / The University of Leicester's Department of Sociology - Seminar Series (2015/2016)
The University of Leicester's Department of Sociology - Seminar Series (2015/2016)
Posted by ld190 at Nov 26, 2015 11:05 AM | Permalink
The Department of Sociology has announced that it will be hosting a series of academic speakers to talk about their cutting-edge research. Topics include: Social integration in Europe and the clustering of status groups of UK Universities.
Seminar 1.
Dr. Ryan Powell, Sheffield Hallam University.
Gypsy-Travellers, Roma and social integration in Europe: on the centrality of childhood and the "we-I balance"
December 9th 2015 at 2pm
Att 002, Attenborough
Seminar Abstract:
Norbert Elias provides a very useful theoretical framework for understanding long-term changes in childhood-adulthood relations at the societal level. Key processes central to this theorization include: the increasing distance between childhood-adulthood; the increasing separation of the social worlds of children and adults; the civilizing of parents; changes in the "we-I balance" towards the "I"; and the gradual conversion of social constraints (family/group) into self-restraints (individualization). Yet variable trajectories are under-developed in Elias' work: the differing nature of interrelated social processes for different "outsider" (or weakly integrated) groups in society were not systematically addressed by Elias. This paper applies his theories on childhood and individualization to Gypsy-Traveller/Roma groups. Drawing on empirical data, it argues that the above processes differ markedly for many Gypsy-Traveller/Roma groups and, coupled with the existence of a very strong group orientation and related (dis)identifications, are central to accounting for their relative lack of social integration. That is, seen through an Eliasian lens, differing processes of childhood and family socialisation are crucial in explaining how Gypsy-Traveller/Roma groups have maintained their own group identity and cultural continuity under intense pressures to assimilation and conformity. The paper concludes that a focus on the we-I balance in relation to extreme "outsider" groups such as Gypsy-Travellers/Roma can also aid an understanding of the relative integration of other weakly integrated groups, such as working-class youth where a Bourdieusian framework tends to predominate. Conversely, empirical examples could also contribute to the refinement of Elias' theories, particularly in terms of understanding different patterns of individualization, childhood, socialisation and integration; and in explaining variable outcomes and the stratified nature of "youth transitions".
Dr. Vikki Boliver,
Are there distinctive clusters of higher and lower status universities in the UK?
February 17th 2016 at 4.30pm
CW 409
Charles Wilson Fourth Floor SR 409 Garendon
Session Abstract:
In 1992 the binary divide between universities and polytechnics was dismantled to create anominally unitary system of higher education for the UK. Just a year later, the first UK university league table was published, and the year after that saw the formation of the Russell Group of self-proclaimed 'leading' universities. This paper asks whether there are distinctive clusters of higher and lower status universities in the UK, and, in particular, whether the Russell Group institutions can be said to constitute a distinctive elite tier. Cluster analysis of publicly available data on the research activity, teaching quality, economic resources, academic selectivity, and socioeconomic student mix of UK universities demonstrates that the former binary divide persists with Old (pre-1992) universities characterised by higher levels of research activity, greater wealth, more academically successful and socioeconomically advantaged student intakes, but similar levels of teaching quality, compared to New (post-1992) institutions. Among the Old universities,Oxford and Cambridge emerge as an elite tier, whereas the remaining 22 Russell Group universities appear to be undifferentiated from the majority of other Old universities. A division among the New universities is also evident, with around a quarter of New universities forming a distinctive lower tier.
Dr.Lisa Mckenzie,
Precarious Lives: living in austere times
March 2nd 2016 at 12pm Noon
Ken Edwards Third Floor Room SR 324
Lisa is the author of the highly regarded Getting By: Estates, Class, and Culture in Austerity Britain published by Policy Press, 2015
Professor Claire Callender,
Birkbeck
Student mothers in HE: two (and more) for the price of one – widening participation and tackling child poverty.
March 9th 2016 at 4.30pm
(part of IWD 2016 events)
Attenborough Seminar Block LR 002
This paper will explore two, usually separate but inter-connected, set of policies: one on widening participation and social mobility, and the other on tackling child poverty and inequality. It does this by calling on the findings from a study which assessed part-time undergraduate courses targeted at low-income mothers, delivered in Sure Start Children's Centres, and run by Birkbeck, University of London and the Open University. By focusing on the perceived benefits of study and their effects on the lives of the mothers, and especially their children's educational trajectories, the paper examines how these two policies, and the thinking underpinning them, can be brought together. It argues that these courses helped widen mothers' access to HE. Their transformational and liberating nature, through the academic study of social sciences, enabled and encouraged these mother's involvement and engagement with their children's learning and education. Such courses, therefore, also have the potential to improve their children's educational attainment. This raises issues about the purpose of HE. It brings into question the widely asserted assumption that universities have a limited role to play in tackling the socio-economic gap in children's underachievement.
Professor Russell King
Geography-Migration-Albania
April 27th at 4.30pm
Att 111, First Floor Seminar Block, Attenborough Building
This seminar starts by briefly exploring the premise that, like other field-based social sciences, a geographer's scholarly work is defined by three axes: a specific discipline, a specialist field of study (which may well be interdisciplinary in nature) and a place or country where that specialist field is empirically investigated. As a geographer-migrationist, my preferred field location for the past decade or so has been Albania. No other country in Europe has had such an intensive experience of migration over the past 25 years. Its current stock of emigrants (1.4 million) equates half the population living in Albania (2.8 million at the 2011 census). The second part of the seminar will draw on my various research projects on Albanian migration and its relationship to the ongoing (under)development of Albania).
Filed under: Sociology
« Previous: 'Margaret Thatcher, from Grantham to Downing Street: Narratives of a Path to Power and Beyond, Approaching a Centenary.' November 2015 Next: Leicester sociologists commit to 'live sociology' »
For Current Staff and Students
The University of Leicester's College of Social Science is due to host a major international conference on Social Science Methodology!
New scholarship available for Social Research Masters 2016/2017
School of Media, Communication and Sociology
Campus based courses
E: mcs-enquiries@le.ac.uk
E: css-dl@le.ac.uk
Research degrees (campus-based and distance learning courses)
E: MCS-Research@le.ac.uk
Bankfield House
132 New Walk
LE1 7JA
107-111 Princess Road East
The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for Bankfield House.
DICE and Sporting Equals present: Leader Board Academy Feb 25, 2019
New report shows shortage of science graduates theory does not add up Aug 20, 2018
Shedding light on historical stories of displacement and forced migration Aug 03, 2018
Expert opinions cover 'smart' clothing, Wuthering Heights, the radical right, football and Zimbabwe Aug 02, 2018
Tor Clark talks popularity of ITV's Love Island and predicts who will win tonight's series final Jul 30, 2018
News and Events - More…
The Sociology Review